SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

Journal article

Following the publication of the original article [1], we were notified that the Flu-iiQ™ table included in the supplementary material of original publication needs to be deleted. The authors were not at liberty to publish the table in full as a number of the items listed are confidential and commercially sensitive. For full details of the Flu-iiQ™ questionnaire please contact Measured Solutions P/L, PO Box 5127, Alphington VIC 3079, Australia (measuredsolutions.com.au). The original article has been corrected.

Authors: Halford, S; Wan, S; Dragoni, I; Silvester, J; Nazarov, B

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: BioMed Central
• Journal: Trials
• Volume: 22
• Issue: 1
• Pages: 550-550
• Article number: 550
• Publication date: 2021-08-19
• DOI: 10.1186/s13063-021-05461-9
• EISSN: 1745-6215
• ISSN: 1745-6215
• Language: English
• Keywords: Randomized controlled trial; 2019-20 coronavirus outbreak; Clinical trial; Virology; Coronavirus disease 2019 (COVID-19); Spike (software development); Internal medicine; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Spike Protein; Pharmacology; Medicine